Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Hum Immunol. 2017 Feb 7;78(4):327–335. doi: 10.1016/j.humimm.2017.02.002

Table 1.

HLA-cSCC Associations in Immunocompetent Patients

HLA ALLELE STUDY RESULTS
Population (Latitude) No. of Cases No. of Controls Association (p-value) Reference
Class I HLA-cSCC Associations

B*58 Italy (41.9°N) 13 220 negative (0.024) [74]
Southern Australia (30.0°S) 34 201 null [75]

Bw4a United States (43.2°N) 238 398 negative (<0.001) [76]

Class II HLA-cSCC Associations

DRB1*01 Italy (41.9°N) 13 220 positive (0.005) [74]
United Kingdom (55.4°N) 12 108 nullb (0.09) [6]
Tropical Island, Saba (17°N) 14 91 null [77]

DRB1*07 Southern Australia (30.0°S) 34 201 positive (<0.01) [75]

DRB1*15 United Kingdom (55.4°N) 12 108 nullc [6]

DRB1*16 United Kingdom (55.4°N) 12 108 nullc [6]

DQB1 United States (38.8°N) 6579 280558 positive (<10−5) [12]

DQA1 United States (38.8°N) 7701 60166 positive (<5*10−8) [13]

Note: p-values for associations that were significant or borderline-significant at the α=0.05 level are reported

a

Bw4 is a serological epitope defined by amino acid residues at positions 77–83. All HLA-B alleles containing the Bw4 epitope are included here (including B*58).

b

Positive association with borderline significance at the α=0.05 level

c

Nonsignificant trend in favor of a negative association (α=0.05)